Personalis (PSNL) just released earnings for the third quarter and the first nine months of 2026, providing updated figures on its cancer genomics business and ongoing investment-driven losses.
Personalis shares now trade at US$15.79, after a mixed stretch that includes a roughly 21% 90 day share price return and a much stronger year to date move of about 101%. The 3 year total shareholder return of around 12x hints at investors reassessing both growth potential and risk around the cancer genomics story.
Scan beyond Personalis and see how other cancer and biotech plays are reacting to similar earnings pressure with the curated 38 healthcare AI stocks.
The share price now hovers just above the average analyst target, after a sharp run that has already re-rated Personalis. The key question is where fair value lies within that narrow gap.
Most Popular Narrative: 4% Overvalued
Personalis currently trades at $15.79 compared with a widely followed narrative fair value of $15.17. This leaves the stock slightly above that framework while still closely aligned with it as a guidepost for expectations.
The main thing that has to go right is that Personalis converts very rapid MRD volume growth, expanding Medicare coverage and international marks, and the shift from legacy contracts into higher-value clinical and biopharma MRD work into sustainable margins and disciplined cash usage, despite current low gross margins and planned 2026 cash burn of about US$100m.
See why 11 investors see Personalis as 4% overvalued.
Result: Fair Value of $15.17 (OVERVALUED)
Still, the Personalis story carries real pressure points, including high cash usage alongside a forecast US$105m loss in 2026 and ongoing reimbursement uncertainty on many NeXT Personal tests.
Find out about the key risks to this Personalis narrative.
Next Steps
If this Personalis update leaves you weighing both the potential and the risks, consider acting quickly and conducting your own stress test of the narrative using the 1 key reward and 3 important warning signs.
Looking for more Personalis investment ideas?
If Personalis has your attention, do not stop here. Broaden your watchlist with focused screeners that surface different types of opportunities before they move out of reach.
- Target potential mispricings by scanning a curated 35 high quality undervalued stocks that highlights businesses with solid fundamentals trading below their implied worth.
- Prioritise resilience first and reduce surprises by filtering for 31 resilient stocks with low risk scores that score well on balance sheet strength and risk checks.
- Hunt for future leaders early by combing through a focused 19 high quality undiscovered gems filled with under-the-radar companies that already show quality in their numbers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com